Biliverdin reductase B as a new target in breast cancer
These data collectively identify BLVRB as a novel metabolic target in breast cancer, distinct from other redox-regulating pathways. This study, along with our recent progress in developing novel specific BLVRB inhibitors, offers a unique translational opportunity for targeted therapies in personalized breast cancer medicine.
Authors
- Lisa E. Malone (ORCID: https://orcid.org/0000-0002-4248-0482)
- Wadie F. Bahou (ORCID: https://orcid.org/0000-0001-6527-8503)
- Julie A. Reisz (ORCID: https://orcid.org/0000-0002-7296-4963)
- Stan Uryasev (ORCID: https://orcid.org/0000-0001-6950-3966)
- Natasha M. Nesbitt (ORCID: https://orcid.org/0000-0001-5549-0383)
- Н. В. Марченко (ORCID: https://orcid.org/0000-0002-7583-8321)
- Joonhyuk Suh
- Angelo D’Alessandro (ORCID: https://orcid.org/0000-0002-2258-6490)
- Evguenia M. Alexandrova (ORCID: https://orcid.org/0000-0002-1480-9877)
Institutions
- New York Blood Center (US)
- University of Colorado Anschutz Medical Campus (US)
- Stony Brook University (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1186/s13058-025-02147-x
- Primary Topic
- Heme Oxygenase-1 and Carbon Monoxide
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- Cancer Center, University of Colorado
- National Cancer Institute